Literature DB >> 10366459

The significance of Erb-b2 immunostaining in cervical cancer.

J Nevin1, D Laing, P Kaye, T McCulloch, R Barnard, P Silcocks, T Blackett, M Paterson, F Sharp, P Cruse.   

Abstract

OBJECTIVE: The aim of this study was to assess the relationship between survival and erb-b2 immunohistochemical staining in patients with early stage cervical carcinoma.
METHODS: Archival specimens for 126 patients with stage IB/IIA cervical carcinoma treated with radical hysterectomy and bilateral pelvic node dissection (RH-BPND) were retrieved and submitted to immunohistochemistry for ERBB2 expression. The association between positive results and poor survival was assessed in a multivariate analysis.
RESULTS: Erb-b2 immunostaining was significantly associated with poor survival (P = 0.0284) but less so than parametrial extension (P = 0.0014) and nodal disease (P = 0.0106). Tumor type (squamous/adenosquamous/adenocarcinoma) and the status of surgical margins were not significantly associated with survival.
CONCLUSIONS: These results supported further investigations of ERBB2 expression as a marker of high-risk disease in patients treated with RH-BPND. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366459     DOI: 10.1006/gyno.1999.5396

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.

Authors:  Elizabeth G Munro; Maneesh Jain; Esther Oliva; Neel Kamal; Subodh M Lele; Maureen P Lynch; Lankai Guo; Kai Fu; Poonam Sharma; Steve Remmenga; Whitfield B Growdon; John S Davis; Bo R Rueda; Surinder K Batra
Journal:  Int J Gynecol Pathol       Date:  2009-03       Impact factor: 2.762

2.  Role of HER-2/neu in Premalignant and Malignant Lesions of Uterine Cervix.

Authors:  Swasti Bajpai; Seema Awasthi; Shyamoli Dutta; Ankita Mittal; Ashutosh Kumar; Faiyaz Ahmad
Journal:  J Clin Diagn Res       Date:  2017-09-01

3.  EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.

Authors:  Li Shen; Yongjie Shui; Xiaojia Wang; Liming Sheng; Zhengyan Yang; Danfeng Xue; Qichun Wei
Journal:  BMC Cancer       Date:  2008-08-12       Impact factor: 4.430

Review 4.  Emerging biological treatments for uterine cervical carcinoma.

Authors:  Patrizia Vici; Luciano Mariani; Laura Pizzuti; Domenico Sergi; Luigi Di Lauro; Enrico Vizza; Federica Tomao; Silverio Tomao; Emanuela Mancini; Cristina Vincenzoni; Maddalena Barba; Marcello Maugeri-Saccà; Giuseppe Giovinazzo; Aldo Venuti
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.